Get notified when NTLA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Clinical Hold (removed) — FDA clinical hold on nex-z trials was lifted in January and March 2026, but the underlying patient death and liver toxicity signal remain a key risk for the program.
Intellia's lonvo-z hits Phase 3 goal; cash runway extends into 2028 after $194.6M raise
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read
Key Changes
-
high
Phase 3 HAELO trial met primary endpoint: lonvo-z cut HAE attacks 87% vs placebo, supporting planned BLA submission and commercial launch in H1 2027.
MD&A: HAE program verify on EDGAR → -
high
FDA clinical hold on nex-z trials lifted after patient death; genomic analysis links liver enzyme elevations to a specific HLA allele.
MD&A: nex-z safety verify on EDGAR → -
high
Securities class action dismissed with prejudice; plaintiffs did not appeal.
Notes: Litigation verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade NTLA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 7, 2026 · How we verify